News | November 08, 2021
Divis Labs PAT at Rs 606.46 cr. in Q2FY22
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Subscribe To Our Newsletter & Stay Updated
